Discover trends, market shifts, and competitive outlooks for the g-csf (granulocyte colony stimulating factors) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
#What Is the Current and Projected Market Size of the G-CSF (Granulocyte Colony Stimulating Factors) Market Through 2034?
The market size of G-CSF (granulocyte colony stimulating factors) has experienced consistent growth in the past years. It is projected to escalate from $5.5 billion in 2024 to $5.72 billion in 2025, with a compound annual growth rate (CAGR) of 3.9%. This growth during the historic period is credited to the rise in cancer cases, robust economic development in burgeoning markets, higher healthcare spending, an upsurge in pharmaceutical research and development expenditure, and government measures.
Strong expansion is predicted for the G-CSF (granulocyte colony stimulating factors) market in the upcoming years, with expectations to reach $7.19 billion by 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth during the forecast period will be driven by factors such as higher cancer rates, escalation in the demand for prophylaxis granulocyte colony-stimulating factor (g-CSF), increased healthcare spending, promising prospects in emerging economies, advancements in technology, and a favorable market for biosimilar drugs. The forecast period will also see key trends like pouring substantial investments in research & development for new and effective medications, a heightened emphasis on mergers and acquisitions for growth, forming strategic alliances, advancements in new drug development, and a targeted approach towards producing biosimilars for neutropenia treatment to enhance revenue and product range.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp
What Are the Primary Drivers Supporting the Market Growth of the G-CSF (Granulocyte Colony Stimulating Factors) Market?
The escalating incidence of cancer is a crucial element propelling the expansion of the G-CSF (granulocyte colony stimulating factor) market. Cancer is deemed the second leading cause of mortality, accounting for 1 in 6 deaths globally. The American Cancer Society, a US-based voluntary health organization with a focus on cancer eradication, projected in January 2023 that there will be 1,958,310 new cancer cases and 609,820 resulting deaths in the US in the same year. G-CSF – a growth factor responsible for white blood cell production in bone marrow, effectively reducing infection and sepsis risks – plays a critical role for cancer patients. G-CSF expedites recovery and cuts down fatality rates from neutropenia after cancer chemotherapy. Moreover, it has been found to lessen infection risks following certain cancer treatments. Consequently, the surge in cancer cases is projected to fuel growth in the G-CSF market.
Which Primary Segments of the G-CSF (Granulocyte Colony Stimulating Factors) Market Are Driving Growth and Industry Transformations?
The G-CSF (granulocyte colony stimulating factors) market covered in this report is segmented –
1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types
2) By Product: Tablet, Capsule, Other Products
3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications
Subsegments:
1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim
2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies
3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim
4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=3466&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the G-CSF (Granulocyte Colony Stimulating Factors) Market?# Market?
North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2024. The regions covered in the G-CS (granulocyte colony stimulating factors) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Are the Most Significant Market Trends in the G-CSF (Granulocyte Colony Stimulating Factors) Market?
Firms involved in the G-CSF (granulocyte colony stimulating factor) market are turning their attention to strategic alliances to advance innovative products and boost their market stake. This industry has seen joint ventures, partnerships, licensing agreements with both companies and academic and research institutions increasing significantly in recent times. For instance, in 2022, the Singapore-based biopharmaceutical firm, Evive Biotech struck an exclusive long-term licensing deal for the distribution of Efbemalenograstim alfa (F-627) in Germany and Switzerland with APOGEPHA, a pharmaceutical company based in Germany. F-627 is a unique non-pegylated, long-lasting dimeric G-CSF fusion protein.
View the full report here:
https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report
What Parameters Are Used to Define the G-CSF (Granulocyte Colony Stimulating Factors) Market?
G-CSF (granulocyte colony stimulating factors) refers to a type of colony-stimulating factor that aids in the bone marrow’s ability to produce more white blood cells. Patients who have specific tumors, neutropenia brought on by some types of chemotherapy, or severe persistent neutropenia unrelated to cancer treatment are all treated with G-CSF. Filgrastim and Granulocyte Colony-Stimulating Factor are other names for it.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3466
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
